financetom
Business
financetom
/
Business
/
Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Antiviral therapeutics developer SIGA Q3 revenue plummets on lower TPOXX deliveries
Nov 6, 2025 1:27 PM

Overview

* SIGA ( SIGA ) Q3 revenue declines to $2.6 mln vs $10 mln yr ago, posts a net loss compared to a profit last year

* Company attributes revenue decline to lower product sales, especially TPOXX deliveries

* SIGA ( SIGA ) focuses on securing new procurement contracts for future revenue growth

Outlook

* SIGA ( SIGA ) focuses on securing new procurement contracts for future revenue growth

Result Drivers

* LOWER PRODUCT SALES - Significant decline in Q3 revenue attributed to reduced TPOXX deliveries

* U.S. GOVERNMENT CONTRACTS - $53 mln oral TPOXX and $26 mln IV TPOXX revenues from U.S. Strategic National Stockpile deliveries

* INTERNATIONAL SALES - $6 mln oral TPOXX sale to international customer, marking fifth sale in six years

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$6.40

Income mln

Analyst Coverage

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved